Global Organ-On-Chip Market Size Grows at a CAGR of 24.15%.

Introduction

Straits Research released its highly anticipated report, “Global Organ-On-Chip Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 174.95 million in 2025 and is projected to expand to USD 1,222.13 million by 2034, registering a compound annual growth rate (CAGR) of 24.15%.

Market Dynamics

A key growth driver for the organ-on-chip market is the increasing demand from pharmaceutical companies to replace or supplement animal models with human microphysiological systems. Companies such as Emulate report that nearly 90% of drugs that pass preclinical animal testing fail in human trials, highlighting the need for more predictive models. Advanced Organ-on-Chip platforms, such as Emulate’s high-throughput systems, allow researchers to run dozens of human organ simulations simultaneously, reducing time and cost for drug screening while improving predictive accuracy. This capability accelerates adoption in pharma R&D pipelines and positions Organ-on-Chip technology as an essential tool for safer and faster drug development.

However, the market faces challenges due to high technological complexity, manufacturing costs, and the early stage of regulatory acceptance. Producing Organ-on-Chip devices requires microfluidics, 3D tissue cultures, and integrated sensors, making standardization and scalability difficult. Additionally, partnerships between firms like MIMETAS and large pharmaceutical companies, adoption remains limited to niche applications, and commercial costs per assay remain significantly higher than traditional preclinical models.

On the other hand, applications into multi-organ systems and AI-driven disease modeling represent significant opportunities for market. Leading companies are developing chips that model complex human physiology, including neuroinflammation, tumor microenvironments, and blood-brain-barrier interactions. These innovations allow personalized drug testing and open avenues in oncology, CNS disorders, and immunotherapy, as well as potential applications in cosmetics and chemical safety testing.

Market Highlights

• Offerings: The services segment dominated the market in 2025.
• Application: The drug discovery & development segment dominated the market with a revenue share of 58.79% in 2025.
• End User: The pharmaceutical and biotechnology companies segment dominated the market in 2025 with a revenue share of 67.34%.
• Regional Insights: North America accounted for 50% market share, driven by high adoption of organ-on-chip models.

Competitive Players

1. ALANTRA
2. Allevi, Inc.
3. Bi/ond
4. BiomimX S.r.l.
5. chiron
6. CN Bio Innovations Ltd
7. Creative Biolabs.
8. Dynamic42 GmbH
9. Elvesys
10. Emulate, Inc.
11. Hesperos, Inc.
12. InSphero
13. LifeNet Health LifeSciences
14. MesoBioTech
15. Mimetas
16. Quris Technologies LTD.
17. Sartorius AG
18. SynVivo, Inc.
19. TissUse GmbH
20. Wyss Institute
21. Others

Recent Developments

Strategic Initiatives

• October 2025: CN Bio, a leading developer of Organ-on-a-chip solutions, launched its PhysioMimix Core, a first OOC solution to deliver validated performance across single-organ, multi-organ, and higher-throughput configurations.

Segmentation

1. By Offerings (2026-2034)
   1. Products
      1. Instrument
      2. Consumables & Accessories
      3. Devices
         1. Liver-on-a-Chip
         2. Lung-on-a-Chip
         3. Intestine-on-a-Chip
         4. Kidney-on-a-Chip
         5. Heart-on-a-Chip
         6. Others
   2. Services
2. By Application (2026-2034)
   1. Drug Discovery & Development
   2. Toxicology Research
   3. Disease Modeling
   4. Others
3. By End User (2026-2034)
   1. Pharmaceutical and Biotechnology Companies
   2. Academic & Research Institutes
   3. Others